Mesothelioma

The woman is suing the MoD, as well as the company her father worked for.

The Shropshire Star revealed last week that the Telford mother, who is in her early 30s but does not want to be identified, was claiming tens of thousands of pounds in damages from the MoD and Rubery Owen, after she was diagnosed with The mother is currently in hospital battling the disease, but doctors have told her she has just weeks or months to live.

She claims her terminal illness was caused by the asbestos fallout from a huge blaze at Central Ordnance Depot Donnington, as it was then known, on June 24, 1983.

Asbestos in the roof of the burning building was scattered over more than 15 sq miles of east Shropshire and more than £165 million damage was caused.

Today, her solicitor Helen Childs, of Reading-based Boyes Turner Solicitors, said they had had a positive response.

Mrs Childs said: “We had somebody e-mail us directly to say he was a witness and a further three people put messages on the Shropshire Star website to say they were there at the time.

“My client is really buoyed up by the responses she has had.

We hope to have lots of people along at our meetings next week.

“It really has given my client qui...

In August 2004, CuraGen signed a Clinical Trials Agreement with the NCI under which the NCI will sponsor several clinical trials to investigate belinostat for the treatment of various cancers, both as a single-agent and in combinationchemotherapy regimens.

In May 2005, TopoTarget announced the signing of a Cooperative Research and Development Agreement (CRADA) with the NCI to conduct preclinical and nonclinical studies on belinostat in order to better understand its antitumor activity and to provide supporting information for clinical trials.

About TopoTargetTopoTarget (OMX – The Nordic Exchange: TOPO) is a biopharmaceutical company, headquartered in Denmark and with subsidiaries in the UK, Germany and the USA,dedicated to finding ''Answers for Cancer'' and developing improved cancer therapies.

TopoTarget is founded and run by clinical cancer specialists and combines years of handson clinical experience with in-depth understanding of the molecular mechanisms of cancer.

Focus lies on highly predictive cancer models and key cancer enzyme regula-tors (mainly HDAC, mTOR, and topoisomerase II inhibitors) and a strong development foundation has been built.

TopoTarget has a broad portfolio of small molecule preclini-cal drug candidates and seven dr...